Partner Content
Category :
Partner Content
/
Press releases
Newsletters and Deep Dive digital magazine
With advertisers preparing to spend up to $15 billion on influencer marketing by 2022, pharmaceutical and biotech companies are increasingly (and carefully) engaging trusted health social influencers to connect more authentically with consumers.
As pharma starts to leverage a multitude of high-engagement channels like influencer marketing, online communities and virtual health services, the industry finds itself in a unique position to reimagine traditional direct-to-consumer (DTC) efforts and peer-to-peer communication. That means going beyond TV ad celebrities or one-off Instagram relationships limited to short-term PR value.
When it comes to motivating consumers to take action with their health, and especially inspiring people to speak to a doctor, pharma needs to be thinking about new ways not just to reach patients but to activate them.
Social health—the digital means by which health consumers engage with each other and their health—has broad applications for the healthcare industry overall. To learn more, read the full article on health-union.com.
The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) has said it will launch a pilot programme in the coming weeks to see how it can evolve the regulation o
The UK healthcare system is confronting unprecedented challenges due to an ageing population and a surge in health issues.
Explore “Innovation as Strategy” framework, providing a guide for employing innovative strategies in life sciences.
In this edition of Deep Dive, Unpacking complex choreography in the biologics patent dance, Alexion examines the urgent need for accelerated access programmes for rare disease treatments, and Putna
It will come as no surprise to anyone in the healthcare space that doctors today are under an inordinate amount of pressure.
We are living in an era of unprecedented advances in cancer treatments with transformative therapies being regularly approved.
Radically Optimize Bi, Tri & Multispecific Antibodies to Enhance Target Discovery, Mechanistic Diversity & Clinical Translation to Maximize the Therapeutic Index & Enhance Combi
Improving Prediction & Translation of ADC Toxicities to Drive More Tolerable ADCs Successfully Into & Through Clinical Development
Get in-depth news, opinions and features on pharma and healthcare sent straight to your inbox